Gritstone Oncology Inc

Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Gritstone Oncology reports strong financials and promising advancements in immunotherapy

Gritstone Oncology Inc showcases financial stability, progress in cancer immunotherapy, and advancements in infectious disease programs. Challenges include data requirements for ongoing studies, while opportunities lie in upcoming data presentations and exploring novel vaccine concepts.

Gritstone Oncology excels in Q1 with promising GRANITE program and samRNA advancements

Gritstone Oncology's Q1 2023 earnings call highlighted strong financials, progress in the GRANITE program, and advancements in the samRNA platform. Challenges include endpoint selection for Phase 3 study and managing pseudo progressors. Opportunities lie in combining immunotherapies for KRAS mutations and exploring adjuvant settings.

Gritstone Oncology reports positive Q1 results and eyes market expansion

Gritstone Oncology's Q1 2024 performance showcased positive outcomes in the GRANITE program and financial stability through strategic funding.
The company's strengths lie in promising immune responses, encouraging PFS data, and a proactive approach to clinical program advancement.
Challenges include data gaps in patient groups and uncertainties around future consortium data, while opportunities abound in market expansion and upcoming data releases.
Overall, Gritstone Oncology's focus on innovative cancer vaccine programs and financial prudence positions them well for future growth and clinical success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Gritstone investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securiti.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Gritstone bio, Inc. (GRTS) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS) investors concerning the Company's possible violations of federal securities laws. On February 12, 2024, Gritstone disclosed that it would be delaying the launch of its COVID-19 vaccine study (the “Phase 2b CORAL Study”) from the first quarter of 2024 to Fall 2024 to “allow use of fully GMP-grade raw materials in the vaccine, wh.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Gritstone bio, Inc. (GRTS) on Behalf of Investors

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Gritstone bio, Inc. (NASDAQ: GRTS) between March 9, 2023 and February 29, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 6, 2024.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Gritstone bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRTS

NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Gritstone securities between March 9, 2023 and February 29, 2024, both dates inclusive (the “Class Period”). Investors have until August 6, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

GRITSTONE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Gritstone bio, Inc. and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 12, 2024, Gritstone disclosed that it would be delaying the launch of its COVID-19 vaccine study (the “Phase 2b CORAL Study”) from the first quarter of 2024 to.

The Law Offices of Frank R. Cruz Announces Investigation of Gritstone bio, Inc. (GRTS) on Behalf of Investors

NEW YORK , June 11, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Gritstone bio, Inc. (NASDAQ: GRTS) between March 9, 2023 and February 29, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

GRTS Investors Have Opportunity to lead Gritstone bio, Inc. Securities Fraud Lawsuit

NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased securities of Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS) between March 9, 2023 and February 29, 2024, inclusive (the “Class Period”).

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Gritstone bio, Inc. (GRTS)

SAN DIEGO--(BUSINESS WIRE)---- $GRTS #GRTS--Robbins LLP is Investigating Allegations that Gritstone bio, Inc. (GRTS) Misled Investors Regarding the Initiation of its Phase 2b CORAL Study.

Gritstone bio, Inc. Investor Notice: Robbins LLP Reminds Stockholders of the GRTS Class Action

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Gritstone bio, Inc. (NASDAQ: GRTS) between March 9, 2023 and February 29, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 6, 2024. SO WHAT: If you purchased Gritstone securities during the Class.

GRITSTONE INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gritstone bio, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GRTS

ATLANTA, June 10, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information, including allegations that: (i) Gritstone would be unable to launch the Phase 2b CORAL Study in the timeframe it had represented to investors; (ii) the foregoing would impair Gritstone's ability to obtain external funding in connection with the Study, thereby negatively affecting Gritstone's ability to maintain its balance sheet and cash position; and (iii) accordingly, Gritstone overstated its ability to successfully develop and commercialize its products.

Class Action Lawsuit Filed on Behalf of Gritstone bio, Inc. (GRTS) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

SAN DIEGO, June 08, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Gritstone bio, Inc. (NASDAQ: GRTS) securities between March 9, 2023 and February 29, 2024. Gritstone is a clinical-stage biotechnology company that engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases.

Stockholder Alert: Robbins LLP Informs Investors of the Class Action Lawsuit Filed Against Gritstone Bio, Inc.

NEW YORK , June 7, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ: GRTS) and certain officers.   The class action, filed in the United States District Court for the Northern District of California, and docketed under 24-cv-03449, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Gritstone securities between March 9, 2023 and February 29, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Pomerantz announces the filing of a class action lawsuit Gritstone bio, Inc. and Certain Officers - GRTS

EMERYVILLE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that management will be participating in the following investor and scientific conferences:

Gritstone bio to Participate in Upcoming Investor and Scientific Conferences

-- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET.

Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024

Gritstone bio (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the appointment of Stephen Webster to its Board of Directors. A veteran finance executive in the biotechnology industry, Mr. Webster has served as an executive for several renowned companies and held key roles in raising capital, business development transactions and operations for over 30 years. The company also announced that Steve Krognes will not stand for re-election at the 2024 Annual Meeting.

Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors

NEW YORK , April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ: GRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS

-- Paper details vaccine design optimization process of Gritstone's “off-the-shelf” or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. Rosenberg of the National Cancer Institute (NCI) --

Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)

Gritstone bio (GRTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -63.39% in 4 Weeks, Here's Why Gritstone bio (GRTS) Looks Ripe for a Turnaround

Gritstone bio's GRANITE program shows promising preliminary results in the treatment of metastatic microsatellite stable colorectal cancer (MSS-CRC).

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

Gritstone (GRTS) plunges after a mid-stage study evaluating its personalized cancer vaccine in certain patients with colorectal cancer failed to achieve its primary endpoint.

Gritstone (GRTS) Plummets 58% in a Week: Here's Why

Gritstone Bio (NASDAQ: GRTS ) stock is falling on Tuesday after the clinical-stage biotechnology company announced the pricing of an underwritten public offering for its shares. This public offering has the company selling 8,333,333 shares of GRTS stock for $1.50 each.

Why Is Gritstone Bio (GRTS) Stock Down 44% Today?

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwriting discounts and commissions and offering expenses.

Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof). All of the shares of common stock, pre-funded warrants and accompanying common warrants are being offered by Gritstone bio. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Gritstone bio Announces Proposed Public Offering

-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction of progression or death with GRANITE vs. control) in a high-risk group, where clinical data are more mature ([95% CI, 0.15-1.38]; 44% censored); >90% of high-risk patients have liver metastases -- -- Short-term molecular response (as defined by protocol) is uninformative due to an unexpectedly persistent ctDNA drop beyond induction chemotherapy; long-term circulating tumor DNA (ctDNA) responses align with PFS trends and favor GRANITE vs. control patients --

Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite St

News for Gritstone Oncology Inc Stock (GRTS)